本文選題：阿比特龍　切入點：未經(jīng)化療　出處：《上海交通大學(xué)學(xué)報(醫(yī)學(xué)版)》2017年11期

【摘要】：目的·評價阿比特龍(AA)聯(lián)合潑尼松治療轉(zhuǎn)移性去勢抵抗性前列腺癌(mCRPC)患者的療效,并分析預(yù)后因素。方法·回顧性分析2012年9月—2016年12月上海交通大學(xué)醫(yī)學(xué)院附屬仁濟醫(yī)院診治的112例mCRPC患者的臨床資料,其中42例先前接受過化療,70例先前未接受過化療。觀察終點為前列腺特異性抗原無進展生存期(PSA PFS)、影像學(xué)無進展生存期(r PFS)以及總生存期(OS)。采用Cox單因素和多因素分析對患者PSA PFS、rPFS以及OS相關(guān)的預(yù)后因素進行分析。結(jié)果·中位隨訪時間20.2個月,59例患者死亡。中位PSA PFS 8.9(7.8~10.0)個月,中位rPFS 9.7(9.0~10.4)個月,中位OS 22.2(20.3~24.1)個月。多因素分析中,先前是否接受化療、粒淋比(≥3 vs3)、血清乳酸脫氫酶水平(≥196 U/L vs196 U/L)、先前內(nèi)分泌治療有效時間(12個月vs≥12個月)、ECOG評分(≤1 vs 2)與mCRPC患者接受AA聯(lián)合潑尼松治療的PSA PFS與rPFS顯著相關(guān),先前是否接受化療、ECOG PS(≤1 vs 2)與OS顯著相關(guān)。結(jié)論·AA聯(lián)合潑尼松治療中國mCRPC患者取得較好療效,先前是否接受化療、ECOG PS(≤1 vs 2)與接受AA治療的mCRPC患者OS顯著相關(guān)。
[Abstract]:Objective to evaluate the efficacy and prognostic factors of Abiproterol combined with prednisone in the treatment of metastatic ovariectomized prostate cancer (mCRPC).Methods the clinical data of 112 patients with mCRPC treated in Renji Hospital affiliated to Shanghai Jiaotong University Medical College from September 2012 to December 2016 were retrospectively analyzed.The end points were PSA PFSV, r PFSand total survival time (PSAs) and total survival time (TFS).The prognostic factors associated with PSA PFSR rPFS and OS were analyzed by Cox single factor and multivariate analysis.Results the median follow-up time was 20.2 months and 59 patients died.The median PSA PFS was 8. 9 / 7 / 10. 0) months, the median rPFS was 9. 7 / 9 / 10.4) months, and the median OS was 22. 2 / 20. 3 / 24. 1) months.In multivariate analysis, whether previously received chemotherapy,The ratio of granulocyte to lymphocyte (鈮，

本文編號：1689199